Potential biomarker of metformin action

被引：20

作者：

He, Ling ^{[1
,2
]}

Meng, Shumei ^{[1
,2
]}

Germain-Lee, Emily L. ^{[3
,4
,5
]}

Radovick, Sally ^{[3
,4
]}

Wondisford, Fredric E. ^{[1
,2
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Metab, Baltimore, MD 21287 USA

[2] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Endocrinol, Baltimore, MD 21287 USA

[3] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21287 USA

[4] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA

[5] Kennedy Krieger Inst, Baltimore, MD 21287 USA

来源：

JOURNAL OF ENDOCRINOLOGY | 2014年 / 221卷 / 03期

关键词：

diabetes; glucose metabolism; liver; metabolism; ACTIVATED PROTEIN-KINASE; CREB-BINDING-PROTEIN; FATTY LIVER-DISEASE; HEPATIC GLUCONEOGENESIS; HEART-FAILURE; MORTALITY; CANCER; PHOSPHORYLATION; MECHANISM; MOUSE;

D O I：

10.1530/JOE-14-0084

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Metformin is a first-line, anti-diabetic agent prescribed to over 150 million people worldwide. The main effect of metformin is to suppress glucose production in the liver; however, there is no reliable biomarker to assess the effectiveness of metformin administration. Our previous studies have shown that phosphorylation of CBP at S436 is important for the regulation of hepatic glucose production by metformin. In current study, we found that CBP could be phosphorylated in white blood cells (WBCs), and CBP phosphorylation in the liver and in WBCs of mice had a similar pattern of change during a fasting time course experiment. These data suggests that CBP phosphorylation in WBCs may be used as a biomarker of metformin action in the liver.

引用

页码：363 / 369

页数：7

共 22 条

[1] Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure [J].